We are pleased to invite investors and analysts to participate in our virtual event on Monday, 12 June 2023, highlighting crovalimab data presented during the congress scientific program on June 9, 2023, and our hematology and nephrology portfolio. 16:30 – 17:30 CEST / 15:30 - 16:30 BST 10:30 – 11:30 am EDT / 7:30 – 8:30 am PDT   The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:30 CEST on the day of the event. > click here   Agenda Welcome Bruno Eschli, Head of Investor Relations Roche hematology franchise and crovalimab deep-dive Peter Ahnesorg, Franchise Head Hematology, Global Product Strategy Key crovalimab data presented at EHA 2023 Prof. Alexander Röth, MD, West German Cancer Center, University Hospital Essen Roche nephrology franchise strategy and pipeline Jay Garg, MD, Global Development Head of Nephrology and Rheumatology Q&A   Access to virtual event (pre-registration required) Please pre-register for our webinar here*.   Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.   A replay of the webcast will be available via > ir.roche.com   *privacy notice   Best regards,
Bruno Eschli Head of Investor Relations	Lilith Esser Investor Relations Manager	Jan-Philipp Schwarzhans Investor Relations Officer

Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com	Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

get the latest news and updates to your inbox.